Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa

Inclusion Criteria:

• Patients who give informed consent for participation in the clinical trial
• Diagnosed 6 months before inclusion
• Drainage fistula with a minimum of 1 subcutaneous tract and 1 cutaneous drainageorifice evaluated clinically and by cutaneous ultrasound. The fistula must have activedrainage 4 weeks prior to inclusion
• Treatment with Adalimumab for at least 12 weeks.
• Normal renal function or moderate chronic renal insufficiency with creatinineclearance values greater than 60 ml/min or serum creatinine less than 1.5 times theupper limit.
• Normal liver function with total bilirubin values less than 1.5 times the upper limitof normal and transaminases < 2.5 times the upper limit of normal.
• Hemogram and coagulation studies within normal values (Leukocytes ≥ 3000, Neutrophils ≥ 1500, Platelets ≥ 100000, hemoglobin>10g/dl).
• Negative blood pregnancy test for patients of childbearing age
• Acceptance by the patient, of childbearing age, to use safe contraceptive methodsthroughout the study, including six months of follow-up.
• Willingness and ability to comply with the visit schedule, treatment plan, clinicaltests and all study procedures. and all study procedures.

Exclusion Criteria:

• Poorly controlled HS requiring additional systemic treatment or change of baselineanti-inflammatory therapy
• Abscess or inflammatory collection > 2 cm adjacent to the fistula to be treated.
• Previous surgical treatment on the draining fistula
• Known history of alcohol abuse in the 6 months prior to study entry
• Active malignancy or patients with a history of a previous malignant tumor.
• Presence or recent history of severe, progressive and uncontrolled hepatic,hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, psychiatricor skin disease
• Congenital or acquired immunodeficiencies
• Positive serology for HIV, HCV or HBV.
• Active COVID-19 infection confirmed by serology and PCR or rapid antigen test
• Allergy to any of the components/excipients of the Investigational Product
• Major surgery or severe trauma in the previous 6 months
• Patients unwilling or unable to comply with study procedures.
• Anticipated need for surgery in the anatomical area for a reason other thanhidradenitis suppurative
• Contraindication to the anesthetic procedure
• Systemic immunomodulatory biologic therapy other than Adalimumab, topical or systemicantibiotics for HS, systemic or intralesional corticosteroids, live vaccines, or anyexperimental treatment or intervention study participation.
• Contraindication of nuclear magnetic resonance with contrast.
• Women who are pregnant, breastfeeding, or of childbearing age who are not using aneffective contraceptive method.
• Patients who are currently participating or have completed participation in a clinicaltrial in a period of less than 3 months or who have participated in an AdvancedTherapies clinical trial at any previous time and have been assigned to anexperimental group.